Biological life cycle

Neogen® Farm Fluid MAX Disinfectant Launches Across Great Britain Livestock & Poultry Markets

Retrieved on: 
Thursday, April 11, 2024

GREATER MANCHESTER, England, April 11, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched Neogen® Farm Fluid MAX in Great Britain and will soon be available in other European markets, subject to global registrations and notifications.

Key Points: 
  • GREATER MANCHESTER, England, April 11, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched Neogen® Farm Fluid MAX in Great Britain and will soon be available in other European markets, subject to global registrations and notifications.
  • This dual-action disinfectant is designed for challenging farm conditions and is formulated for use as part of a Neogen Pathogen Programme.
  • An extension of the respected Farm Fluid product line, Neogen Farm Fluid MAX is specially designed to be applied as part of coccidiosis control protocols.
  • The typical recommendation would be to utilize Neogen Farm Fluid MAX as the third step of the programme, following the cleaning of all surfaces with Farm-Foam™ EVO and an initial application of Neogen Viroxide Super™ disinfectant.

R21 anti-malaria vaccine is a game changer: scientist who helped design it reflects on 30 years of research, and what it promises

Retrieved on: 
Thursday, April 25, 2024

Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.What makes malaria such a difficult disease to beat?Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.

Key Points: 


Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.

What makes malaria such a difficult disease to beat?

  • Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.
  • Additionally, the malaria parasite goes through four life cycle stages.
  • Medical researchers have been trying to make malaria vaccines for over 100 years.

How does the R21/Matrix-M vaccine work?

  • An antigen is any substance that causes the body to make an immune response against that substance.
  • We targeted the sporozoites, which is the form that the mosquito inoculates into your skin.
  • Read more:
    Two new malaria vaccines are being rolled out across Africa: how they work and what they promise

A child dies every minute from malaria in Africa. Why are children more susceptible than adults?

  • The age you’re most likely to die of malaria in Africa is when you are one year old.
  • For the first six months you are protected largely by your mother’s immunity and the antibodies she transfers during pregnancy.
  • Without malaria, children would be healthier in general — the disease makes you susceptible to other infections.

What about the pace of vaccine rollouts?

  • We’ve been disappointed that it’s taken more than six months to roll out the R21 vaccine since it was approved in October last year.
  • Compare that to a COVID-19 vaccine from Oxford and AstraZeneca that was approved on New Year’s Eve 2020 and rolled out in several countries the very next week.

How big a role will vaccines have in the fight to eradicate malaria?

  • Nobody is quite sure how many of the older tools such as insecticides and bed nets we need to carry on with.
  • Anti-malaria medication only lasts for days and parasites are building up resistance against these drugs as well.
  • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.
  • The Serum Institute of India, our manufacturing and commercial partner, can produce hundreds of millions of doses each year.


Adrian Hill receives funding from government and charitable funders of malaria vaccine development. He has received funding awarded to the University of Oxford from the Serum Institute of India to support clinical trials of the R21/Matrix-M vaccine. He may benefit for a share of any royalty stream to Oxford University from the vaccine.

How worried should I be about cryptosporidiosis? Am I safe at the pool?

Retrieved on: 
Thursday, February 15, 2024

More than 700 cases of this gastrointestinal disease were reported in Queensland in January, which is 13 times more than in January last year.

Key Points: 
  • More than 700 cases of this gastrointestinal disease were reported in Queensland in January, which is 13 times more than in January last year.
  • Read more:
    What lies beneath: the bugs lurking in your swimming pool

What causes cryptosporidiosis, and who is affected?

  • Cryptosporidum hominis only affects humans and is the major cause of recent outbreaks in Australia, while Cryptosporidium parvum can also affect animals.
  • The infection is spread by spores called oocysts in the stools of humans and animals.
  • Cryptosporidiosis is more prevalent in young children, particularly those under five, but the disease can affect people of any age.

So how do we catch it?

  • The largest recorded outbreak occurred in Milwaukee in 1993 where 403,000 people were believed to have been infected.
  • As few as ten oocysts can cause infection, making it possible for contaminated drinking water to affect a very large number of people.
  • Oocysts have been found in foods such as fresh vegetables and seafood but these are not common sources of infection in Australia.

What about chlorine?

  • Young children and in particular children in nappies are known to increase the potential for disease transmission in recreational water.
  • Proper nappy changing, frequent bathroom breaks and showering before swimming to remove faecal residue are helpful ways to reduce the risk.

Some sensible precautions


Other measures you can take to reduce yours and others’ risk of cryptosporidiosis include:
avoid swimming in natural waters such as rivers and creeks during and for at least three days after heavy rain
avoid swimming in beaches for at least one day after heavy rain
avoid drinking untreated water such as water from rivers or springs. If you need to drink untreated water, boiling it first will kill the Cryptosporidium
avoid swallowing water when swimming if you can
if you’ve had diarrhoea, avoid swimming for at least two weeks after it has resolved
avoid sharing towels or linen for at least two weeks after diarrhoea has resolved
avoid sharing, touching or preparing food that other people may eat for at least 48 hours after diarrhoea has resolved
wash your hands with soap and water after going to the bathroom or before preparing food (Cryptosporidium is not killed by alcohol gels and sanitisers).
Not all cases of diarrhoea are due to cryptosporidiosis. There are many other causes of infectious gastroenteritis and because the vast majority of the time recovery is uneventful you don’t need to see a doctor unless very unwell. If you do suspect you may have cryptosporidiosis you can ask your doctor to refer you for a stool test.
Vincent Ho does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Rheonix Inc. Publishes Cyclospora cayetanensis Data in Collaboration With FDA Center for Food Safety and Applied Nutrition

Retrieved on: 
Wednesday, January 10, 2024

announces joint publication with the Food and Drug Administration (FDA) of collaborative data confirming the detection of Cyclospora cayetanensis (C. cayetanensis) in produce samples.

Key Points: 
  • announces joint publication with the Food and Drug Administration (FDA) of collaborative data confirming the detection of Cyclospora cayetanensis (C. cayetanensis) in produce samples.
  • The data verify the performance of the fully automated Rheonix C. cayetanensis™ assay developed under a Research Collaboration Agreement (RCA) between Rheonix and the Office of Applied Research and Safety Assessment (OARSA) within the Center for Food Safety and Applied Nutrition (CFSAN) of the FDA.
  • The Rheonix C. cayetanensis assay is based on genetic targets developed and published by the FDA and is processed using Rheonix reagents and consumables on the Rheonix Encompass Optimum™ workstation.
  • The assay is now available for use by food and environmental testing laboratories (for more information, please visit the Rheonix website ).

'We could eradicate malaria by 2040' says expert after revolutionary vaccine is approved by WHO

Retrieved on: 
Tuesday, October 3, 2023

Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.

Key Points: 
  • Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.
  • The Conversation Weekly spoke to chief investigator Adrian Hill, who is also director of the Jenner Institute at the University of Oxford, about this revolutionary vaccine.

Why is the R21/Matrix vaccine a game-changer?

    • The best vaccine prior to this was about 50% over a year, and lower than that over three years.
    • The big difference is how you can manufacture it at a scale that is really needed to protect most of the children who need a malaria vaccine in Africa.
    • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.

Why has developing a malaria vaccine been so difficult?

    • Malaria is not a virus, it’s not a bacterium.
    • This is one of the reasons that malaria is super complex.
    • If you can get a really good vaccine for one of those, you will break the cycle of transmission.
    • It’s a silent infection until it gets into the blood and starts multiplying inside your red blood cells.
    • So the sporozoite is a natural target to try and kill the parasite before it multiplies very quickly.

Tell us about past attempts to develop a malaria vaccine

    • In about 1943, there was a trial of the whole malaria parasite vaccine candidate in New York with zero efficacy.
    • And then within 10 years we had 5,000 candidates because everyone hoped that the gene they had sequenced might be a malaria vaccine.

Why aren’t vaccines for whole parasites effective against malaria?

    • It’s the same reason that just getting infected once by malaria doesn’t give you protection against the next infection.
    • In the areas of malaria where we test our vaccines in Africa, some children get up to eight episodes in three or four months.
    • They get quite unwell with the first and three weeks later they’re having a second bout and so on.

Will we ever eradicate malaria entirely?

    • Malaria is very high on the list of diseases we want to eradicate.
    • I don’t think it’s going to happen in five years or 10 years, but it should happen in something like 15 years.

Global 5D Building Information Modeling Market Report 2022: Increasing Use of IoT in Construction Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 13, 2023

The "Global 5D Building Information Modeling Market Size, Share, Growth Analysis, By Offering Type, By Project Lifecycle, By Application, By End User - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global 5D Building Information Modeling Market Size, Share, Growth Analysis, By Offering Type, By Project Lifecycle, By Application, By End User - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The construction management process can be significantly impacted by 5D BIM software when it comes to cost information.
  • The Global 5D Building Information Modeling Market is segmented based on the Offering Type, Project Life Cycle, Application, End-User and region.
  • Although there is a substantial upfront cost associated with 5D building information modelling, there are numerous benefits and potential financial savings.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target

Retrieved on: 
Tuesday, February 28, 2023

Providence, RI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder and member of the board of directors Dr. Jonathan Kurtis, MD, PhD, has been awarded a new patent for his discovery related to malaria, a third parasite target called PfCDPK-5 that can potentially be used to interdict the parasite at multiple stages in the malaria cycle. This discovery builds on Dr. Kurtis’ previous discoveries that have defined the powerful roles of PfGARP and PfSEA in controlling the malaria parasite’s ability to replicate and grow within its human host. The latest patent is for the discovery that demonstrates the role of antibodies to PfCDPK-5 in preventing merozoites from escaping infected red blood cells and thus attenuates parasite multiplication in the bloodstream.

Key Points: 
  • If combined with the new target PfCDPK-5 and PfSEA, the vaccine has the potential to shut down the parasite at multiple points in its cycle.
  • In coming months, Dr. Kurtis will work to optimize the formulation of his vaccine prior to IND submission and first in humans testing.
  • This medicine will be an additional focus of Ocean Biomedical’s development pipeline in 2023 and will address a massive unmet need.
  • “Falciparum malaria is a leading cause of death in children world-wide and our global malaria treatment strategy relies almost exclusively on artemisinin-based drugs.

Rational Vaccines' Herpes Vaccine RVx1001 Shows Promise as a Viral Vector Platform to Express Malaria Proteins and Confer Protection against Malaria Infection in Mice According to a Recent Study Published in Vaccines

Retrieved on: 
Tuesday, May 10, 2022

WOBURN, Mass. and OXFORD, England, May 10, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced that the Company's attenuated herpes simplex virus type-1 (HSV-1)-vaccine RVx1001 can be utilized as a viral vaccine vector to protect against malaria infections.

Key Points: 
  • Research shows company's novel HSV-1-derived viral vaccine has significant potential to produce vaccines to combat infectious diseases including malaria.
  • The study, "An Attenuated HSV-1 Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection Against Infectious Sporozoite Challenge," was published in Vaccines and can be accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875294/
    The published study reported on the development of a highly efficacious trivalent malaria vaccine using the Rational Vaccines RVx1001 vaccine as a vector.
  • The construction of the HSV-1 vectored vaccine expressed three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3, and TMP21) as fusion proteins with the VP26 viral capsid protein.
  • "These data show that the Rational Vaccines HSV-1 vaccine can be effectively utilized as a vector platform to protect against malaria and other infectious diseases.

Amlan International Launches Two New Natural Alternatives to Antibiotics for Poultry and Livestock

Retrieved on: 
Wednesday, April 27, 2022

To help producers recapture this protection, Amlan International, the animal health business of Oil-Dri Corporation of America, has launched two new natural products Phylox Feed and NeutraPath that help optimize intestinal health and production economics in the absence of antibiotics.

Key Points: 
  • To help producers recapture this protection, Amlan International, the animal health business of Oil-Dri Corporation of America, has launched two new natural products Phylox Feed and NeutraPath that help optimize intestinal health and production economics in the absence of antibiotics.
  • Phylox Feed is a natural alternative to anticoccidial drugs and vaccines that can help producers increase profitability.
  • Coccidiosis, caused by Eimeria species, is an enteric disease that can have a significant economic impact on animal protein production.
  • Oil-Dri Corporation of America doing business as Amlan International is a publicly traded stock on the New York Stock Exchange (NYSE: ODC).